Subject: Quick intro, accelerating NC-217 in vivo readouts for your January gate

From: Maya Patel [maya.patel@crl.com](mailto:maya.patel@crl.com)
To: Dr. Li Chen [li.chen@novacura.bio](mailto:li.chen@novacura.bio)
Date: Fri, Nov 7, 2025, 9:06 AM ET

Hi Dr. Chen,

I am Maya Patel from Charles River. I lead oncology discovery services. We work with several biotech teams in late lead optimization to run rapid xenograft efficacy packages and, when needed, parallel non-GLP tolerability to de-risk IND plans.

I saw NovaCura recently hired a translational lead for oncology and assumed NC-217 may be approaching in vivo confirmation. If you are planning a January decision gate, we can usually deliver first tumor growth readouts in a 6 to 8 week window from compound receipt, with biomarker add-ons like pERK and Ki-67.

If helpful, I can share a 1-page outline of a typical scope and timeline.

Best,
Maya Patel
Director, Oncology Discovery Services
Charles River Laboratories

---

Subject: Re: Quick intro, accelerating NC-217 in vivo readouts for your January gate

From: Dr. Li Chen [li.chen@novacura.bio](mailto:li.chen@novacura.bio)
To: Maya Patel [maya.patel@crl.com](mailto:maya.patel@crl.com)
Date: Fri, Nov 7, 2025, 1:18 PM ET

Hi Maya,

We are evaluating partners for NC-217 in vivo work.
Send the outline.

Li

---

Subject: Re: Quick intro, accelerating NC-217 in vivo readouts for your January gate

From: Maya Patel [maya.patel@crl.com](mailto:maya.patel@crl.com)
To: Dr. Li Chen [li.chen@novacura.bio](mailto:li.chen@novacura.bio)
Date: Fri, Nov 7, 2025, 2:03 PM ET

Hi Dr. Chen,

Thanks. Here is a concise outline so you can see if this aligns (happy to refine on a call):

Proposed efficacy package (non-GLP):

* 2 xenograft models (often colorectal plus a lung or other solid tumor model).
* 3 arms per model (vehicle, low, high), typically 8 to 10 animals per arm.
* Endpoints: tumor growth inhibition, survival as needed.
* Biomarkers: pERK and Ki-67 IHC with digital image analysis (optional tissue banking for future RNA-seq).
* Interim weekly data drops, final integrated report.

Typical timing (from compound receipt):

* Model prep: ~2 weeks
* On-study and first readouts: 4 to 6 weeks
* Total to first data: 6 to 8 weeks

Optional early safety (if board wants de-risking before GLP tox):

* 7-day non-GLP rat dose range finding (DSA group), can run in parallel to efficacy.

To tailor this, I need a few quick data points:

1. Which two models are you leaning toward?
2. Any fixed endpoints beyond tumor volumes (e.g., pERK, Ki-67 confirmed)?
3. When could you ship compound?
4. Are you thinking DRF now or only after efficacy?

If it is easier, we can cover in a 30 min discovery call next week.

Best,
Maya

---

Subject: Re: Quick intro, accelerating NC-217 in vivo readouts for your January gate

From: Dr. Li Chen [li.chen@novacura.bio](mailto:li.chen@novacura.bio)
To: Maya Patel [maya.patel@crl.com](mailto:maya.patel@crl.com)
Date: Mon, Nov 10, 2025, 8:32 AM ET

Hi Maya,

High level:

* Two models: a colorectal xenograft we have used before, plus a PD-L1 high lung cancer model (newer for us).
* Endpoints: tumor growth inhibition, pERK and Ki-67. If you can run IHC and analysis, that helps.
* Timeline: first readouts in ~6 to 8 weeks. We have a go/no-go end of January tied to IND plans for early Q2 next year.
* Compound: batch release this Friday, can ship early next week.
* Early safety: board is asking for a short non-GLP rat tolerability / DRF in parallel if feasible, but efficacy is priority.
* Budget expectation for efficacy (incl biomarkers): USD 250K to 300K. We are also speaking to WuXi and Labcorp for comparison.

We should talk.

Li

---

Subject: Re: Quick intro, accelerating NC-217 in vivo readouts for your January gate

From: Maya Patel [maya.patel@crl.com](mailto:maya.patel@crl.com)
To: Dr. Li Chen [li.chen@novacura.bio](mailto:li.chen@novacura.bio)
Date: Mon, Nov 10, 2025, 9:11 AM ET

Hi Dr. Chen,

This is exactly the kind of program we can support, and your timeline is workable if we receive compound next week. We will come prepared to address:

* implantation consistency for the PD-L1 high lung model
* keeping first readouts inside your January gate
* pricing in your expected range, with an optional parallel DRF scenario

Letâ€™s do a 30 to 40 min discovery call to finalize scope and timeline. I can also bring a discovery biology lead to confirm model selection and QC details.

Does Thu Nov 13 at 11:00 AM ET work? If not, send a couple of slots and I will adjust.

Best,
Maya Patel
